Mineralys TherapeuticsMLYS +2.19%35 Current Ratio is 44.33 as of Mar. 2026, which is 145% above its 10-year median of 18.06. GuruFocus rates MLYS with a GF Score™ of 35/100. The stock has 1 warning sign investors should review. Among 1,416 Biotechnology companies, Mineralys Therapeutics ranks better than 98.23% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Mineralys Therapeutics's current ratio for the quarter that ended in Mar. 2026 was 44.33.
Mineralys Therapeutics has a current ratio of 44.33. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Mineralys Therapeutics's Current Ratio or its related term are showing as below:
MLYS'
s Current Ratio Range Over the Past 10 Years
Min: 0.29 Med: 18.06 Max: 44.33
Current: 44.33
During the past 6 years, Mineralys Therapeutics's highest Current Ratio was 44.33. The lowest was 0.29. And the median was 18.06.
MLYS's Current Ratio is ranked better than 98.23% of 1416
companies
in the Biotechnology industry
Industry Median: 3.885
vs MLYS: 44.33
Mineralys Therapeutics (NAS:MLYS) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Mineralys Therapeutics Current Ratio Related Terms
Mineralys Therapeutics Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MLYS vs IDYA, DFTX, TARS: Current Ratio Comparison
For the Biotechnology subindustry, Mineralys Therapeutics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mineralys Therapeutics Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Mineralys Therapeutics's Current Ratio distribution charts can be found below:
* The bar in red indicates where Mineralys Therapeutics's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mineralys Therapeutics (MLYS) has a Current Ratio of 44.33 as of Mar. 2026. This is 145% above median its historical median of 18.06. Over the past decade, Mineralys Therapeutics' Current Ratio has ranged from 0.29 to 44.33. According to the industry distribution chart, Mineralys Therapeutics ranks #25 out of 1416 companies in the Biotechnology industry, placing it in the top 1.8%.
Is Mineralys Therapeutics' Current Ratio too high?
Mineralys Therapeutics' current Current Ratio of 44.33 is 145% above median its 10-year median of 18.06. Over the past 10 years, this metric has ranged from a low of 0.29 to a high of 44.33. The Biotechnology industry median Current Ratio is 3.89. Mineralys Therapeutics' value of 44.33 is 1041.1% above this industry median. Based on the distribution chart, Mineralys Therapeutics ranks #25 out of 1416 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Mineralys Therapeutics has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Mineralys Therapeutics' Current Ratio compare to IDYA and DFTX?
According to the Biotechnology industry distribution chart, Mineralys Therapeutics ranks #25 out of 1416 companies for Current Ratio. This places Mineralys Therapeutics in the top 2% of its industry — outperforming the majority of peers. The industry median Current Ratio is 3.89. Mineralys Therapeutics' value of 44.33 is 1041.1% above this benchmark. Historically, Mineralys Therapeutics' own Current Ratio has ranged from 0.29 to 44.33 over the past decade. While the company's 10-year median is 18.06 vs. the industry median of 3.89, Mineralys Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mineralys Therapeutics's current Current Ratio of 44.33 is 1041.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mineralys Therapeutics's current Current Ratio is 44.33, which is 145% above median its own 10-year median of 18.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mineralys Therapeutics stock overvalued right now?
Mineralys Therapeutics (MLYS) has a current Current Ratio of 44.33. The current Current Ratio is 44.33, which is 145% above median its 10-year median of 18.06 and 1041.1% above the Biotechnology industry median of 3.89. Mineralys Therapeutics' overall GF Score™ is 35/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Mineralys Therapeutics (MLYS), the current Current Ratio is 44.33 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.
35GF Score
Get the complete analysis for MLYS
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MLYS has been successfully added to your 
